TY - JOUR T1 - Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00185-2018 VL - 5 IS - 1 SP - 00185-2018 AU - Lowie E.G.W. Vanfleteren AU - Anders Ullman AU - Anita Nordenson AU - Anders Andersson AU - Kristina Andelid AU - Leonardo M. Fabbri Y1 - 2019/02/01 UR - http://openres.ersjournals.com/content/5/1/00185-2018.abstract N2 - A current hot topic in COPD is that two “fixed triple” combinations of an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) in a single inhaler have become available for patients with COPD, and a third triple therapy is in advanced development with the first large randomised clinical trial (RCT) recently published in Lancet Respiratory Medicine [1]. The triple therapies available in a single inhaler are: beclomethasone-dipropionate/formoterol/glycopyrronium (BDP/FF/G); fluticasone-furoate/vilanterol/umeclidinium (FLF/VI/UMEC); and budesonide/glycopyrronium/formoterol (B/G/F).Triple inhaler therapy in COPD might in some real-life situations be useful outside of the strict indications reported by the registration agencies, but at the same time in some other situations it could be better avoided, even when recommended http://ow.ly/CbOe30njXV2 ER -